{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(11)"],"submitter":["Duflot T"],"pubmed_abstract":["Cardiovascular diseases (CVD) are the leading cause of premature death and disability in humans that are closely related to lipid metabolism and signaling. This study aimed to assess whether circulating lysophospholipids (LPL), lysophosphatidic acids (LPA) and monoacylglycerols (MAG) may be considered as potential therapeutic targets in CVD. For this objective, plasma levels of 22 compounds (13 LPL, 6 LPA and 3 MAG) were monitored by liquid chromatography coupled with tandem mass spectrometry (HPLC/MS2) in different rat models of CVD, i.e., angiotensin-II-induced hypertension (HTN), ischemic chronic heart failure (CHF) and sugen/hypoxia(SuHx)-induced pulmonary hypertension (PH). On one hand, there were modest changes on the monitored compounds in HTN (LPA 16:0, 18:1 and 20:4, LPC 16:1) and"],"journal":["Metabolites"],"pagination":["784"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8621392"],"repository":["biostudies-literature"],"pubmed_title":["Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?"],"pmcid":["PMC8621392"],"pubmed_authors":["Thuillet R","Bellien J","Bauer F","Tu L","Groussard D","Duflot T","Leuillier M","Messaoudi H","Guignabert C","Azhar S","Richard V","Feugray G","Humbert M"],"additional_accession":[]},"is_claimable":false,"name":"Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?","description":"Cardiovascular diseases (CVD) are the leading cause of premature death and disability in humans that are closely related to lipid metabolism and signaling. This study aimed to assess whether circulating lysophospholipids (LPL), lysophosphatidic acids (LPA) and monoacylglycerols (MAG) may be considered as potential therapeutic targets in CVD. For this objective, plasma levels of 22 compounds (13 LPL, 6 LPA and 3 MAG) were monitored by liquid chromatography coupled with tandem mass spectrometry (HPLC/MS2) in different rat models of CVD, i.e., angiotensin-II-induced hypertension (HTN), ischemic chronic heart failure (CHF) and sugen/hypoxia(SuHx)-induced pulmonary hypertension (PH). On one hand, there were modest changes on the monitored compounds in HTN (LPA 16:0, 18:1 and 20:4, LPC 16:1) and","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-22T06:00:43.788Z","creation":"2022-02-11T13:32:44.224Z"},"accession":"S-EPMC8621392","cross_references":{"pubmed":["34822442"],"doi":["10.3390/metabo11110784"]}}